FINWIRES · TerminalLIVE
FINWIRES

Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial

By

(Updates with the latest stock move in the headline and in the first paragraph.)

Rezolute (RZLT) shares rose about 16% in Tuesday afternoon trading after the company said that six of eight participants enrolled in a phase 3 trial of ersodetug in uncontrolled hypoglycemia caused by tumor hyperinsulinism have already met the responder criterion for the study's primary endpoint.

The primary endpoint of the study, which aims to enroll 16 patients with insulinoma or non-islet cell tumors, is the number of participants achieving at least a 50% reduction from baseline in intravenous glucose requirements within the 8-week pivotal treatment phase, the company said.

Rezolute said ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.

Topline results for the fully enrolled open-label phase 3 study are expected in H2, Rezolute said.

Price: $4.18, Change: $+0.57, Percent Change: +15.65%

Related Articles

Wire

Top Midday Gainers

Marvell Technology (MRVL) shares rose 29% after multiple news outlets reported Nvidia (NVDA) Chief Executive Officer Jensen Huang called the chipmaker the next "trillion-dollar company."More than 76.2 million shares traded intraday, compared with a daily average of about 27.6 million.Hewlett Packard Enterprise (HPE) reported fiscal Q2 earnings ahead of analysts' forecasts late Monday.Shares jumped 16%, with intraday trading volume rising to over 115.4 million from a daily average of roughly 20.2 million.Victoria's Secret (VSXY) raised its full-year sales and earnings guidance. The shares began trading under the ticker "VSXY" on the New York Stock Exchange on Tuesday. It previously traded under "VSCO".Shares soared 48%, with over 6 million shares traded.Price: $283.35, Change: $+63.92, Percent Change: +29.13%

$HPE$MRVL$VSXY
Wire

OpenAI Adds ZoomInfo to Codex for Work as a Sales Intelligence App

Microsoft-backed (MSFT) OpenAI said Tuesday that ZoomInfo Technologies (GTM) is now natively available inside OpenAI Codex for Work as a business-to-business go-to-market intelligence app.The integration brings ZoomInfo's verified company intelligence and contact data into Codex, the company said. Users can ask Codex to identify target accounts, build prospect lists, or analyze companies, and Codex will run the matching ZoomInfo skill and return a verified answer, the company said.Price: $3.34, Change: $-0.49, Percent Change: -12.70%

$GTM$MSFT
Wire

Update: Market Chatter: General Dynamics to Invest $200 Million to Restart Texas Munitions Facility

(Updates with the company's response in the fourth paragraph.)General Dynamics (GD) will invest $200 million and unwind its partnership with Turkish defense contractor Repkon as it seeks to start production of 155mm artillery shells at a Texas plant, Bloomberg reported Monday, citing people familiar with the matter.The munitions manufacturing equipment supplied by Repkon failed to meet required standards and is expected to be replaced by hardware and management from privately held Deterrence Defense, according to the news outlet.The additional $200 million investment would come on top of the $591 million contract the US Army awarded to General Dynamics for the Texas facility, which was designed to operate three production lines capable of manufacturing 30,000 155mm artillery shells per month, the report added.A General Dynamics spokesperson toldin an emailed response that "General Dynamics Ordnance and Tactical Systems and [its] US Army customer have reached an agreement on a path forward for the Mesquite facility, which includes additional GDOTS investment to complete the project."(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$GD